



## ASX ANNOUNCEMENT

### Lumos Diagnostics General Meeting – Chair Address

**MELBOURNE, Australia (22 December 2022)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care (POC) diagnostic technologies, today releases the Chairs’ Address for the 2022 General Meeting as follows:

Good morning. My name is Sam Lanyon. I am the Chair of Lumos Diagnostics and I would like to welcome you to this General Meeting. This General Meeting has been convened to seek approval from the Shareholders of Lumos Diagnostics to proceed with the issue of Convertible Notes which will provide up to A\$8.0M in funding to support the growth of the Company.

At our Annual General Meeting that was held on 30 November 2022, we presented a detailed review of Lumos’ operations and the exciting growth opportunities that we see for the Company following its recent restructuring and the appointment of industry veteran Doug Ward as Chief Executive Officer. Rather than going over these again, I refer you to the Chairman’s Address and CEO’s presentation from the AGM that has been lodged with the Australian Stock Exchange. However, for the purposes of this Meeting, I would just like to remind you that Lumos is operating in the rapid, point-of-care diagnostics space—a market which is experiencing strong growth as a result of the benefits this type of testing provides to the healthcare system from efficiency gains and improved healthcare outcomes. Furthermore, by being able to provide a comprehensive set of capabilities that span the initial concept and design of point-of-care tests, through to product and clinical development, and finally to their manufacture for commercial sale, Lumos provides a much needed offering in this market. Currently, there are very few outsource providers that have capabilities which span the entire value chain in the same way that Lumos does. Finally, Lumos has a proprietary connected point-of-care test reader platform which is becoming increasingly important as healthcare systems start to require that the results from point-of-care tests become part of complex care pathways and integrated with electronic medical record systems. In view of this, we believe Lumos has a very promising future by providing a much needed attractive offering in a growing market and this view is supported by our recent contracts wins with Alden, Hologic and others.

The funds raised from the issue of these Convertible Notes will enable Lumos to take advantage of some of the exciting commercial opportunities available to the Company. These funds will primarily be applied to assist Lumos in expanding its pipeline of contract development and manufacturing business, supporting the commercial launch of the Company’s own point-of-care tests as they are approved various markets, and also provide working capital to support the Company’s operations.



The structure of the Convertible Notes, and the terms for their issue and conversion have been provided in detail in the Notice of Meeting that was lodged with the Australian Stock Exchange on 21 November 2022. The Convertible Notes to be approved at this General Meeting can provide up to A\$8.0 million in funding for Lumos. These will be issued in two tranches with the first tranche of A\$4.0 million to be issued subject to securing Shareholder Approval at this Meeting. The second tranche of A\$4.0 million is subject to mutual agreement between Lumos and the Investors which will only be sought should it be considered necessary or desirable by the Company as it focuses on growing the cash generating activities within its development and services business. Lumos believes that even in the absence of any additional investment or unbudgeted material commercial contracts, the combined funds from both tranches of Convertible Notes should be sufficient to support the Company's operations into early FY24.

With this introduction and context, I would now like to proceed to Matters of Business for this General Meeting—namely to seek Shareholder Approval for the issue of up to A\$8.0 million of Convertible Notes in Lumos as set out in the Notice of Meeting dated 21 November 2022.

This announcement has been authorised for release to the market by the Lumos Board of Directors.

###

### **About Lumos Diagnostics**

*Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos branded POC tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com) or [febridx.com](https://febridx.com)*

### **Media Contact:**

Matthew Wright  
Director, NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 451 896 420



**Investor Relations Contact:**

Matthijs Smith

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 411 137 080

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

+61 3 9087 1598